Literature DB >> 12741714

A newly characterized SCN5A mutation underlying Brugada syndrome unmasked by hyperthermia.

Ngai-Shing Mok1, Silvia G Priori, Carlo Napolitano, Ngai-Yin Chan, Mohamed Chahine, Ghayath Baroudi.   

Abstract

Febrile illness has been rarely reported to modulate ST segment elevation in right precordial leads on ECG or even precipitate ventricular fibrillation in patients with Brugada syndrome. We report the case of a patient whose Brugada ECG pattern was unmasked by hyperthermia secondary to acute cholangitis. Serial ECGs showed progressive attenuation of ST segment elevation as body temperature gradually returned to normal. Structural heart disease was ruled out. Intravenous flecainide injection reproduced a less remarkable ST segment elevation. Genetic screening demonstrated a single amino acid substitution (H681P) in the SCN5A gene, thus confirming the diagnosis of Brugada syndrome. In vitro expression of this newly characterized genetic defect revealed novel biophysical abnormalities consisting of a shift in both steady-state activation and inactivation, resulting in a 60% reduction of sodium window current. Thus, SCN5A-H681P mutation induces a significant loss of transmembrane current and is clinically associated with a pathologic phenotype that is elicited by hyperthermia. Overall the observed clinical features are in agreement with previous observations and strongly suggest that fever may be an environmental modifier among Brugada syndrome patients with a detrimental (and possibly arrhythmogenic) effect on cardiac repolarization.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12741714     DOI: 10.1046/j.1540-8167.2003.02379.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  19 in total

1.  Brugada electrocardiographic pattern induced by fever.

Authors:  Pablo Lamelas; Carlos Labadet; Fernando Spernanzoni; Cristian Lopez Saubidet; Paulino A Alvarez
Journal:  World J Cardiol       Date:  2012-03-26

Review 2.  Drug-induced spatial dispersion of repolarization.

Authors:  Charles Antzelevitch
Journal:  Cardiol J       Date:  2008       Impact factor: 2.737

3.  A novel SCN5A mutation V1340I in Brugada syndrome augmenting arrhythmias during febrile illness.

Authors:  Kaveh Samani; Geru Wu; Tomohiko Ai; Mossaab Shuraih; Nilesh S Mathuria; Zhaohui Li; Yoshiro Sohma; Enkhsaikhan Purevjav; Yutao Xi; Jeffrey A Towbin; Jie Cheng; Matteo Vatta
Journal:  Heart Rhythm       Date:  2009-05-18       Impact factor: 6.343

4.  Protein kinase A-dependent biophysical phenotype for V227F-KCNJ2 mutation in catecholaminergic polymorphic ventricular tachycardia.

Authors:  Amanda L Vega; David J Tester; Michael J Ackerman; Jonathan C Makielski
Journal:  Circ Arrhythm Electrophysiol       Date:  2009-08-25

Review 5.  Genetic testing of inherited arrhythmias.

Authors:  Carlo Napolitano
Journal:  Pediatr Cardiol       Date:  2012-03-17       Impact factor: 1.655

6.  Differential thermosensitivity in mixed syndrome cardiac sodium channel mutants.

Authors:  Mena Abdelsayed; Colin H Peters; Peter C Ruben
Journal:  J Physiol       Date:  2015-08-12       Impact factor: 5.182

Review 7.  Brugada syndrome.

Authors:  Charles Antzelevitch
Journal:  Pacing Clin Electrophysiol       Date:  2006-10       Impact factor: 1.976

Review 8.  Brugada pattern: a comprehensive review on the demographic and clinical spectrum.

Authors:  Hassan Abbas; Sohaib Roomi; Waqas Ullah; Asrar Ahmad; Ganesh Gajanan
Journal:  BMJ Case Rep       Date:  2019-07-11

9.  Genetically engineered SCN5A mutant pig hearts exhibit conduction defects and arrhythmias.

Authors:  David S Park; Marina Cerrone; Gregory Morley; Carolina Vasquez; Steven Fowler; Nian Liu; Scott A Bernstein; Fang-Yu Liu; Jie Zhang; Christopher S Rogers; Silvia G Priori; Larry A Chinitz; Glenn I Fishman
Journal:  J Clin Invest       Date:  2014-12-15       Impact factor: 14.808

Review 10.  Brugada syndrome: from cell to bedside.

Authors:  Charles Antzelevitch; Pedro Brugada; Josep Brugada; Ramon Brugada
Journal:  Curr Probl Cardiol       Date:  2005-01       Impact factor: 5.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.